CHMP Upholds Negative Opinion for UCB's Cimzia
Posted on: Friday, 21 March 2008, 09:00 CDT
UCB has announced that the European Medicines Agency Committee for Medicinal Products for Human Use has rejected the appeal, following CHMP refusal of the marketing authorization application for Cimzia in the treatment of patients with Crohn's disease, a chronic and debilitating inflammatory disease.
This decision comes following an appeal the company filed after a previous negative opinion was adopted by the CHMP in November 2007 and only applies to UCB's filing for Cimzia in Crohn's disease in the EU.
Olav Hellebo, senior vice president UCB & president inflammation operations, said: "The CHMP's negative opinion is disappointing for UCB. Nevertheless, we are pleased that specific safety and quality concerns raised by the committee in November, were resolved through the appeal process."
Source: Datamonitor
Related Articles
- CHMP Upholds Negative Opinion for the EU Application for Cimzia(R) in the Treatment of Crohn's Disease
- UCB: Early Data on Cimzia(R) From the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients
- UCB to Appeal European Negative Opinion on Cimzia
- CHMP Adopts Negative Opinion on Appeal on European Application For Natalizumab for the Treatment of Crohn's Disease
- UCB to Appeal European Negative Opinion on CIMZIA(R) for the Treatment of Patients With Crohn's Disease
- UCB Seeks Approval for New Crohn's Disease Treatment
- UCB Seeks OK of Crohn's-Disease Drug
- UCB: Phase III Study Shows CIMZIATM is an Effective and Well-Tolerated Treatment for Crohn's Disease
- UCB drug shows good results in Crohn's disease
 |
 |
User Comments (0)
RSS Feeds